Clinical trials: Steatosis
NAFLD, NASH - Nonalcoholic Steatohepatitis
A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations
Liver disease (NAFLD) and (NASH) are a rapidly increasing population health threat driven primarily by diet and lifestyle. Fibrotic liver disease, culminating in cirrhosis, is frequently asymptomatic so it is common for a patient…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver, Fatty Liver
- Trial name
- SUNN (NCT03726827)
- Testing
- Fibroscan screening
- Where
- United States
- Volunteers
- 1,006 people, healthy volunteers welcome
- Sponsor
- Fatty liver Foundation
Obesity
Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
The goal of this clinical trial is to investigate the effects of tocotrienol-rich fraction vitamin E supplementation on liver enzymes in overweight and obese children with non-alcoholic fatty liver disease as compared to placebo.
- Trial name
- NCT05905185
- Testing
- Tocotrienol-rich fraction vitamin E (TRF)
- Where
- Malaysia
- Volunteers
- 29 people
- Sponsor
- National University of Malaysia
Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight
Hepatoprotective Measures for Children at High Risk of NAFLD
Non Alcoholic Fatty Liver Disease (NAFLD) is a spectrum of disease, ranging from simple fatty deposition (steatosis) to inflammation (steatohepatitis), fibrosis, cirrhosis, and end-stage liver failure.
- Conditions
- Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight, Acute Lymphoblastic Leukemia
- Trial name
- NCT06918080
- Testing
- Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise
- Where
- 2 sites in Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
NAFLD, NASH With Fibrosis
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
To examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
- Conditions
- NAFLD, NASH With Fibrosis, Liver Fibrosis
- Trial name
- NCT05506488
- Testing
- Dasatinib 100 MG + Quercetin (1000 MG)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non-Alcoholic Fatty Liver Disease
The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study
Non-alcoholic fatty liver disease (NAFLD) is a liver disease, caused by storage of fat in the liver. The most-important risk-factors are being overweight, and disorders in sugar and cholesterol handling of the body.
- Trial name
- NLA2 (NCT05712603)
- Testing
- FIB4-score, Vibration controlled transient elastography, Enhanced Liver Fibrosis test
- Where
- 3 sites in Netherlands
- Volunteers
- 655 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
MASH, MASLD
Global Research Initiative for Patients Screening on MASH
GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe…
- Conditions
- MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver
- Trial name
- GRIPonMASH (NCT05651724)
- Where
- 13 sites in Belgium, Czechia and 8 more
- Volunteers
- 10,000 people
- Sponsor
- Julius Clinical
Non Alcoholic Fatty Liver
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
assessment of NAFLD among diabetic, pre-diabetic and non diabetic participants Using Non Invasive Methods.And correlation between lab and radiological methods .
- Trial name
- NCT04553796
- Testing
- fibroscan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
Non Alcoholic Steatohepatitis
The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin and flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to…
- Trial name
- NCT03377153
- Testing
- hesperidin and flaxseed, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis, Portal Hypertension
- Trial name
- ENDO-MASH (NCT07877272)
- Testing
- Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Muenster
Non-Alcoholic Fatty Liver Disease, Body Composition
Predicting Obesity Consequences Using Body Measure and Urine Metabolomics
This is a prospective observational study which will recruit up to 1200 participants over a two-year period to investigate whether non-invasive methods such as bioelectrical impedance analysis parameters and urine metabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Body Composition, Electric Impedance
- Trial name
- NCT04989062
- Testing
- Fibroscan, Bioelectrical impedance analysis, Urine unclear magnetic resonance metabolomics
- Where
- Taiwan
- Volunteers
- 1,200 people
- Sponsor
- Chang Gung Memorial Hospital
Nonalcoholic Steatohepatitis, Liver Diseases
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.
- Trial name
- NCT00267670
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northwestern University
Non Alcoholic Fatty Liver Disease
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
The central hypothesis of this proposal is that a reduction in hepatic mitochondrial function is the main pathophysiology behind NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non alcoholic steatohepatitis).
- Trial name
- NCT01327443
- Testing
- Weight loss, Exercise
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Missouri-Columbia
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
Evaluation of Multi-Organ Metabolism and Perfusion in Non-Alcoholic Fatty Liver Disease (NAFLD) by Total Body Dynamic PET Scan on EXPLORER
- Trial name
- EXPLORER (NCT04165343)
- Testing
- Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Coronary Disease, Non-alcoholic Fatty Liver Disease
Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease
Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, which is one of the major risk factors of coronary heart disease (CHD).
- Conditions
- Coronary Disease, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques
- Trial name
- NILS-R-CHD (NCT02779946)
- Testing
- Fibro Scan, PNPLA3
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- University of Leipzig
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
- Trial name
- STELLAR-3 (NCT03053050)
- Testing
- SEL
- Where
- 298 sites in United States, Argentina and 25 more
- Volunteers
- 808 people
- Sponsor
- Gilead Sciences
Non-alcoholic Fatty Liver Disease
Adiponectin and Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease (NAFLD)
In peripheral blood; monocytes and macrophages are found in two phenotype; proinflammatory M1 and anti-inflammatory M2 phenotypes.
- Trial name
- NCT01472120
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM)
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
The Sponsor is developing the test medicine, cotadutide, for the potential treatment of non-alcoholic steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) with chronic kidney disease.
- Conditions
- Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease
- Trial name
- NCT05294458
- Testing
- cotadutide solution for injection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
NAFLD, MASLD
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Dietary intakes of saturated fatty acids remain well above nutritional recommendations for most European countries. This may progressively lead to a pro-inflammatory context and the alteration of lipid metabolism in the liver.
- Conditions
- NAFLD, MASLD, Mild Inflammatory Context
- Trial name
- CnC-TOTUM448 (NCT06047847)
- Testing
- TOTUM-448
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Valbiotis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.